Table 2.
Univariate and multivariate overall survival analyses of poor prognostic factors (n = 85)
| Factors |
Univariate
|
Multivariate
|
||||
|
Total patients, (n = 85), n(%)
|
MST (months)
|
P value
|
HR
|
95%CI
|
P value
|
|
| Age, years | ||||||
| < 80 | 62 (73) | 37.8 | 0.718 | |||
| ≥ 80 | 23 (27) | 58.7 | ||||
| Sex | ||||||
| Male | 45 (53) | 37.2 | 0.378 | |||
| Female | 40 (47) | 46.5 | ||||
| Neoadjuvant chemotherapy | ||||||
| Yes | 3 (4) | 36.0 | 0.956 | |||
| No | 82 (96) | 46.5 | ||||
| Preoperative CA 19-9 level, U/mL | ||||||
| < 37 | 55 (65) | 46.5 | 0.504 | |||
| ≥ 37 | 30 (35) | 43.4 | ||||
| TMPRSS4 | ||||||
| Positivity | 46 (54) | 25.3 | < 0.001 | 2.33 | 1.08-5.08 | 0.032 |
| Negativity | 39 (46) | 1.0 | ||||
| Histology, tub1/tub2 | ||||||
| Yes | 68 (80) | 46.5 | 0.752 | |||
| No | 17 (20) | 36.0 | ||||
| Tumor stage, pT3/T4 | ||||||
| Yes | 24 (28) | 22.0 | 0.002 | 2.26 | 1.06-4.81 | 0.035 |
| No | 61 (72) | 59.4 | 1.0 | |||
| Pathological tumor size, mm | ||||||
| < 30 | 43 (51) | 0.017 | 1.0 | |||
| ≥ 30 | 42 (49) | 33.7 | 1.32 | 0.65-2.65 | 0.439 | |
| Lymphatic invasion (ly) | ||||||
| Yes | 22 (26) | 16.3 | < 0.001 | 1.33 | 0.62-2.84 | 0.461 |
| No | 63 (74) | 75.3 | 1.0 | |||
| Venous invasion (v) | ||||||
| Yes | 34 (40) | 22.0 | < 0.001 | 1.93 | 0.91-4.07 | 0.086 |
| No | 51 (60) | 59.4 | 1.0 | |||
| Neural invasion (ne) | ||||||
| Yes | 39 (46) | 33.3 | 0.058 | 0.60 | 0.26-1.40 | 0.237 |
| No | 46 (54) | 58.7 | 1.0 | |||
| Tumor infiltrative type c (IFN c) | ||||||
| Yes | 13 (15) | 33.7 | 0.081 | 1.18 | 0.58-2.42 | 0.648 |
| No | 72 (85) | 58.7 | 1.0 | |||
| Lymph node metastasis | ||||||
| Yes | 40 (47) | 25.6 | 0.004 | 1.44 | 0.60-3.46 | 0.412 |
| No | 45 (53) | 75.3 | 1.0 | |||
| Resection status, | ||||||
| R0 | 67 (79) | 46.6 | 0.022 | 1.0 | ||
| R1 | 18 (21) | 24.5 | 2.21 | 1.08-4.52 | 0.030 | |
| Adjuvant chemotherapy | ||||||
| Yes | 49 (58) | 36.0 | 0.229 | |||
| No | 36 (42) | 75.3 | ||||
CA19-9: Carbohydrate antigen 19-9; CI: Confidence interval; HR: Hazard ratio; MST: Median survival time; tub1: Well-differentiated tubular adenocarcinoma; tub2: moderately differentiated tubular adenocarcinoma; TMPRSS4: Transmembrane serine protease 4.